Announcements Trials
Browse Landscape

Status

No longer available 1

Sponsor Class

INDUSTRY 1

Study Type

Expanded_access 1

Sponsor

Cancer Type

CNS 1Breast 1

Conditions

Breast Neoplasms 17Colorectal Neoplasms 6Stomach Neoplasms 4HER2-positive Breast Cancer 4Carcinoma, Non-Small-Cell Lung 3Brain Neoplasms 3Neoplasms 2Adenocarcinoma Of Esophagus 2Uterine Neoplasms 1Uterine Cervical Neoplasms 1Urologic Neoplasms 1Triple Negative Breast Neoplasms 1Ovarian Neoplasms 1Neoplasms by Site 1HER2-positive Metastatic Breast Cancer 1HER2-positive Gastric Cancer 1Gallbladder Neoplasms 1Esophageal Neoplasms 1Cholangiocarcinoma 1Breast Diseases 1Biliary Tract Neoplasms 1Advanced Unresectable or Metastatic Solid Malignancy 1

Interventions

Pemetrexed 9Carboplatin 7pembrolizumab 6Cisplatin 6130-nm albumin-bound paclitaxel 6Paclitaxel 5Nivolumab 5Gemcitabine 5palbociclib 4napabucasin 4durvalumab 4Fulvestrant 4Bevacizumab 4ribociclib 3osimertinib 3abemaciclib 3Mitomycin 3Irinotecan 3Fluorouracil 3Drug Therapy 3Anastrozole 3Albumin-Bound Paclitaxel 3selpercatinib 2pralsetinib 2patritumab 2ficlatuzumab 2exemestane 2atezolizumab 2Watchful Waiting 2Trabectedin 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Neoplasms by Site × tucatinib × Clear all
NCT03424473 2020-02-25

Expanded Access Use of Tucatinib for HER2+ Metastatic Breast Cancer

Seagen Inc.

No longer available
BreastCNS

Brain Neoplasms, Breast Diseases, Breast Neoplasms, Neoplasms, Neoplasms by Site

Data powered by HemOnc (CC BY 4.0) Colophon âš¡